Spots Global Cancer Trial Database for Imatinib Mesylate in Treating Patients With Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Imatinib Mesylate in Treating Patients With Metastatic Melanoma
Official Title: Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma
Study ID: NCT00027586
Interventions
Study Description
Brief Summary: RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
Detailed Description: OBJECTIVES: * Determine the clinical activity of imatinib mesylate (STI571) in patients with metastatic melanoma. * Determine the side effects of this drug in these patients. * Correlate molecular studies with responsiveness to this drug in these patients. OUTLINE: Patients receive oral imatinib mesylate (STI571) twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 21-78 patients will be accrued for this study within 6-15 months.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Kevin Kim, MD
Affiliation: M.D. Anderson Cancer Center
Role: STUDY_CHAIR
Name: Menashe Bar-Eli, PhD
Affiliation: M.D. Anderson Cancer Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
